8:00 am Check in & Coffee
8:50 am Chairs Opening Remarks
Navigating the Funding & Partnering Challenge: Insights from Investors, Pharma & Biotechs on Diverse Funding Strategies for GBM Research
9:00 am Panel Discussion: How Deal Making & Investment is Changing the Future Landscape for GBM
Synopsis
- Setting the bar/considerations/criteria for investing or partnering
- Analyzing what level of strategic alignment is necessary
- Assessing preclinical models for investment/partnership appeal
- Reviewing public markets vs Private markets
- Exploring how to generate sufficient data to move to collaboration/investment?
- Discussing which mechanisms/targets are appealing or up-and-coming
9:45 am Matchmaking Roundtables
Synopsis
10:45 am Morning Break and Networking
Crossing Boundaries in Delivery: Overcoming the Blood-Brain Barrier in GBM
11:15 am Exploring Cutting-Edge Focused Ultrasound Techniques to Unlock New Treatment Pathways for Glioblastoma
Synopsis
- Overview of the use of focused ultrasound in combination with microbubbles to create transient, safe and targeted opening of the blood brain barrier to aid drug delivery
- Reviewing key findings from clinical trials and preclinical studies for a range of disease types that support the safety and feasibility of the technology as a method for enhancing drug delivery
- Examining future opportunities and challenges for the technology in combination with promising drug candidates for better treatment of GBM & wider CNS tumors
- Revealing ongoing investigations into using FUS for immune stimulation in GBM
11:45 am Panel Discussion: Overviewing & Investigating Success Stories of Crossing the BBB: What are the Mechanisms of Penetration & How Does this Effect Drug Efficacy?
Synopsis
- Discussing new technologies emerging that manipulate the BBB to deliver therapeutic agents directly to the tumor site
- Recounting case studies of success stories in crossing the BBB – how can this be applied?
- Examining the standard differences in delivery between the US and Europe
12:30 pm Highlighting the Success of Vorasidenib for IDH-mutant Glioma: Development History and Current Approaches
Synopsis
- Presenting the history of vorasidenib’s clinical development and its success in slowing tumor progression in patients with IDH-mutant low grade gliomas
- Incorporating translational data to inform subsequent clinical trials for patients with recurrent IDH-mutant gliomas
- Developing vorasidenib for additional high-risk patients with IDH-mutant gliomas
1:00 pm Lunch
Transforming GBM Clinical Trial Development: Applying Key Learnings & Frameworks to Shape Future Success
2:00 pm Goldspire™: A Unique Platform for Personalized, Whole Tumor-Derived Immunotherapy with Compelling Clinical Data in Glioblastoma
Synopsis
- Turning the complexity of the tumor against itself
- Personalized Immunotherapy stimulating tumor Immunogenic Cell Death
- Compelling Phase 1b data leading into ongoing Phase 2b
2:30 pm Roundtable – Preparing for Clinical Trial: Designing a Framework of Communication for Optimal Patient Welfare & Sponsor Outcomes
Synopsis
- Discussing the importance of creating clear, structured communication pathways between clinical trial sponsors, investigators, and patients to ensure transparent and efficient information exchange
- Designing clinical trial protocols that prioritize patient welfare, including informed consent processes, safety monitoring, and addressing patient concerns
- Optimizing communication frameworks to enhance trial efficiency and outcomes, focusing on strategies to align sponsor objectives with patient needs and regulatory requirements
Unlocking the Potential of Combination Therapies for Glioblastoma: Advancing Treatment Outcomes
3:15 pm MT-125 Inhibits Non-Muscle Myosin IIA & IIB, Synergizes with both Radiation & Oncogenic Kinase Inhibitors & Prolongs Survival in Glioblastoma
Synopsis
- MT-125 increases cytoplasmic ROS, induces DNA damage and ferroptosis, prolongs survival in murine GBM models as a monotherapy, and synergizes with radiation.
- MT-125 stimulates oncogenic kinase signaling in glioblastoma through a novel ROSdriven mechanism that induces oncogene addiction, creating synthetic lethality when it is combined with oncogenic kinase inhibitors.
- Combining MT-125 with an FDA-approved PDGFR inhibitor in a murine GBM model significantly improves median survival over either drug alone, and produces prolonged survival in over 40% of mice.